The April 2020 issue of Pharmafocus is available to read free online now!
pharmafile | April 1, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, UK, US, coronavirus, generic medicines, pharma, rare disease, real world data, real-world data
The latest monthly edition of Pharmafocus, the April 2020 issue, is available to read for free online now!
There’s one big story on everyone’s mind, and with the whirlwind of information (and misinformation) around the COVID-19 pandemic, it’s easy to get disorientated. The latest issue of Pharmafocus aims to cut through that by providing a blow-by-blow account of some of the key milestones on the journey to where we are today.
But business ploughs on even in a global crisis, and we also bring you the latest in pharma, biotech and healthcare, from the news that Big Pharma stands as one of the most profitable industries in the US, to the findings of Sir Michael Marmot’s report into health inequality in England, which argued that a decade of austerity policies are behind the first stall in English life expectancy in a century.
Besides all the latest news on the COVID-19 pandemic and beyond, the latest issue includes a feature on the role of generic medicines in the US market and how their original purpose of promoting healthy competition is being undermined through loopholes in the existing system.
In our second feature, we also look at how real-world data may be the key to bolstering and streamlining drug valuation negotiations around the world to ensure key therapies are fairly sold to healthcare services at a price they can afford, providing immediate, unfettered access to the patients that need them.
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
